Us Bancorp \De\ Cassava Sciences Inc Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Cassava Sciences Inc stock. As of the latest transaction made, Us Bancorp \De\ holds 323 shares of SAVA stock, worth $914. This represents 0.0% of its overall portfolio holdings.

Number of Shares

323

Previous 602 46.35%

Holding current value

$914

Previous $7,000 28.57%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$9.57 - $35.08 $2,670 - $9,787	-279 Reduced 46.35%	323 $9,000
Q2 2024 Aug 06, 2024	SELL	$12.35 - $26.11 $28,442 - $60,131	-2,303 Reduced 79.28%	602 $7,000
Q1 2024 May 07, 2024	SELL	$18.44 - $26.41 $2,360 - $3,380	-128 Reduced 4.22%	2,905 $58,000
Q4 2023 Feb 09, 2024	BUY	$12.64 - $30.11 $4,563 - $10,869	361 Added 13.51%	3,033 $68,000
Q3 2023 Nov 03, 2023	SELL	$16.64 - $25.32 $81,303 - $123,713	-4,886 Reduced 64.65%	2,672 $44,000
Q2 2023 Aug 09, 2023	BUY	$21.59 - $27.88 $2,266 - $2,927	105 Added 1.41%	7,558 $185,000
Q1 2023 May 09, 2023	SELL	$23.46 - $36.44 $18,251 - $28,350	-778 Reduced 9.45%	7,453 $179,000
Q4 2022 Feb 13, 2023	BUY	$27.82 - $44.16 $41,090 - $65,224	1,477 Added 21.87%	8,231 $243,000
Q3 2022 Oct 27, 2022	BUY	$16.33 - $51.06 $28,005 - $87,567	1,715 Added 34.03%	6,754 $282,000
Q2 2022 Aug 01, 2022	BUY	$17.22 - $38.47 $13,758 - $30,737	799 Added 18.84%	5,039 $142,000
Q1 2022 May 11, 2022	BUY	$32.6 - $53.05 $15,713 - $25,570	482 Added 12.83%	4,240 $157,000
Q4 2021 Feb 11, 2022	BUY	$36.77 - $90.91 $12,575 - $31,091	342 Added 10.01%	3,758 $164,000
Q3 2021 Nov 10, 2021	BUY	$41.79 - $135.3 $80,445 - $260,452	1,925 Added 129.11%	3,416 $212,000
Q2 2021 Aug 05, 2021	BUY	$32.15 - $89.72 $28,645 - $79,940	891 Added 148.5%	1,491 $127,000
Q1 2021 Apr 28, 2021	BUY	$7.09 - $87.95 $4,254 - $52,770	600 New	600 $27,000

Others Institutions Holding SAVA

# of Institutions

205

Shares Held

13.9M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $113M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account